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pathogen. However, the cost implications of these strategies have not been addressed in light of these results. Our objective was to estimate the incremental effect on healthcare costs associated with targeted decolonization and universal decolonization compared with screening and isolation, which we considered to be the current standard of care. If either of these 2 strategies were found to be less costly than screening and isolation, the benefits of implementing one of these strategies would be to not only improve health but also decrease use of healthcare resources.
METHODS

Decision Analysis Model
We developed a static decision analysis model, programmed in Microsoft Excel, that compared the effects of the above 3 strategies for preventing infections in adult ICUs: (1) screening and isolation, (2) targeted decolonization, and (3) universal decolonization ( Table 1) . 9 Using data from the REDUCE MRSA trial and cost and utilization estimates from published sources, we simulated the effects of each of the 3 strategies on healthcare costs, ICU days, and BSis for 1 year, assuming a hospital with 1,000 annual ICU admissions. Because the trial did not measure effects outside of the ICU, we only modeled ICU impact. The primary perspective was that of the healthcare system. Be-cause this was strictly a cost analysis, no quality-of-life measures were incorporated, nor were health states assigned dollar values.
Model Inputs: Percentage of Patients Placed on Contact Precautions
We assumed that the background percentage of patients who arrive at the ICU and have test results positive for MRSA or have a known recent history of MRSA infection or colonization was 11% (Table 2 ). This estimate was based on the ICU MRSA importation rate reported from the baseline period in all arms of the REDUCE MRSA trial,9 and it remained unchanged during the implementation phase for the arms that continued screening. For the universal decolonization arm, knowledge of MRSA importation decreased in the implementation phase to 4%, likely because of cessation of screening and possibly because of effects of decolonization for patients readmitted to the ICU. Therefore, under the universal decolonization strategy, fewer persons were modeled as being placed on contact precautions. For this cost analysis, it was not necessary to model the "true" percentage of patients colonized with MRSA or the relationship between MRSA colonization and the rate of BSI. The percentage of patients with test results positive for MRSA is primarily important in the model because it affects the number of persons who are placed on contact precautions and therefore affects costs. For the universal colonization strategy, 4% of patients were placed on contact precautions (and therefore incurred the associated costs) because they had some known history of MRSA colonization or infection, but this percentage should not be interpreted as directly relating to any "true" colonization rate.
Model Inputs: Risk of BSI Using data from the REDUCE MRSA trial, the baseline incidence of BSI was assumed to be 19.63 cases per 1,000 ICU admissions, equivalent to approximately 5 infections per 1,000 ICUdays ( Table 2 ). The risk of BSI under the 3 different strategies was also derived from the REDUCE MRSA trial, which reported as-assigned adjusted hazard ratios of 0.98, 0.77, and 0.55 for the screening and isolation, targeted de-colonization, and universal decolonization strategies, respectively9. These results were relative to the pre-trial time period, in which all arms were performing screening and isolation. To compare the targeted decolonization and universal decolonization strategies to screening and isolation, we adjusted the results of those strategies so as to be relative to the long-standing gold standard of screening and isolation. 11 This resulted in the relative risk of BSI being 1.00, 0.7857, and 0.5612 for the screening and isolation, targeted decolonization, and universal decolonization strategies, respectively. Estimate based on the trial results reported by Huang et al.9 This differs from the other strategies, because under the universal decolonization strategy, ICU screening was stopped and active decolonization was occurring for all patients. As the intervention progressed, patients who were readmitted may have been less likely to be identified as MRSA positive. Patients with an earlier ICU admission would be less likely to be screened for MRSA and less likely to acquire MRSA because of universal decolonization. In the trial, 47% of patients with a history of MRSA had a previous admission in the past year. The fact that this 4% value is lower than for the other 2 strategies does not imply anything about the "real" colonization rate. The only impact of this value on the cost results is that it means fewer persons are put on contact precautions under the strategy of universal decolonization. 'Equivalent to 4.99 bloodstream infections per 1,000 ICU-days. dIn the published report of the trial, 9 the effectiveness of the strategies was reported relative to the baseline (preintervention ) period. We have here adjusted those results so as to make the screening and isolation strategy the reference. "Low" and "high" represent 95% confidence intervals.
Model Inputs: Costs and ICU-Days
Parameter estimates related to the base case are shown in Table 3 . Intervention costs were derived from the literature. Intervention-related costs are the costs of screening, contact precautions, and decolonization. Where possible, preference was given to estimates that were more recent and were from the United States. The estimates used in most of the recent literature did not vary substantially, with the exception of the cost of an MRSA screening test and the cost of mupirocin. Variation in screening costs were primarily related to whether the screening was assumed to be performed using the more costly polymerase chain reaction (PCR) test or the less costly chromogenic agar culture. Variation in literature estimates of the cost of mupirocin primarily related to whether generic or trade mupirocin was assumed to be used. In our base case, we assumed the chromogenic agar culture was used for screening (as it was in nearly all hospitals of the REDUCE MRSA trial) and that generic mupirocin was used for de-colonization. We also assumed that positive chromogenic agar cultures would not require confirmatory tests, and therefore we assumed no difference in screening costs between positive and negative screens. Any additional labor costs involved in applying mupirocin were assumed to be negligible, and be-cause patients are typically bathed at least once a day as part of usual care, we assumed that the cost of bathing with chlorhexidine cloths does not require any additional labor. Cost estimates reflect the "steady state;" we did not attempt to estimate start-up costs, such as those that might be associated with training staff. All cost estimates are in $US, adjusted to year 2012 using the consumer price index.
We used estimates from the literature to estimate the incremental hospital days and cost of a BSI (and therefore the incremental savings associated with preventing an infection). Hassan et al1 3 estimated that the incremental hospital-days associated with a hospital-acquired infection (not specifically BSI) was 3.296. In addition, they estimated that the cost of an additional hospital-day once an infection was acquired was 24% higher than the cost of an uninfected day. Dasta et al 1 6 estimated that the mean cost of an ICU-day (after day 3) was $4,385 (after adjusting to 2012 dollars). Applying the above estimates, we estimated the incremental cost of a BSI to be $17,920 (3.296 x [4,385 + (0.24 x 4,385)]). This estimate is consistent with the estimated incremental cost of BSis reported by Kilgore et al2 5 ($22,371 in year 2012 dollars), who, like Hassan et al13, used a large US database and implemented methods to control for heterogeneity and endogeneity biases. All differences among the 3 strategies in hospital days and general ICU costs (not including intervention costs) were assumed to be due entirely to differences in the incidence of BSis and their effects on length of stay and cost per day.
To test the sensitivity of the model results, we varied several important parameters (baseline incidence of BSI, reduction in BSI associated with universal decolonization, and incremental ICU cost of BSI) over a wide range. In addition, we estimated the differences between the 3 screening strategies under a number of alternative scenarios to the base case. For example, we included a scenario in which the PCR test, rather than chromogenic culture, is used to test for MRSA, and a scenario in which trade, rather than generic, mupirocin is used for decolonization. Another scenario included only those costs estimated to be variable in the short run. In their study of variable versus fixed costs of hospital care, Roberts et al'4 treated labor and overhead as fixed in the short run and estimated that only 16% of all hospital costs (corresponding to healthcare worker supplies) were avoidable in the short run. Therefore, in this scenario, we assumed that the incremental cost of a BSI was 16% of our base case estimate, and we assumed no incremental cost for labor to don and doff gowns and gloves. These lengths of stay were applied to the screening and isolation and targeted decolonization strategies. For universal decolonization, in which patients are not screened for MRSA colonization, the length of stays were calibrated so as to be the same as stays in the other 2 strategies, except for any reductions caused by prevention of bloodstream infections. ' Estimates reported in Hassan et al13 were for all hospital-acquired infections and all units. We assumed these would apply to bloodstream infections that occurred in the ICU and that the additional hospital-days would be in the ICU.
" Because we use this estimate for the incremental costs of additional days within a stay, we used the mean cost as reported by Dasta et al"' for days 3 and later. The mean cost per ICU-day reported by Dasta et al 16 was not specifically for uninfected days. However, given the relatively low incidence of hospitalacquired infections (about 6% as reported in Hassan et al" ), we treated this as a reasonable estimate for the cost of an uninfected ICU-day. ' Percentage increase (24% ) in uninfected cost per day as estimated by Hassan et al" applied to estimated cost per ICU-day of Dasta et al.'" ' The low value of $2,880 is 16% of the base case estimate and is an estimate of short-run marginal costs that includes only healthcare worker supplies. 
RESULTS
Over the course of l year at a hospital with 1,000 annual adult ICU admissions, we estimated that a strategy of universal decolonization would prevent 9 BSis compared with a strategy of screening and isolation (11 vs 20) and 4 BSis compared with a strategy of targeted decolonization (11 vs15; Table  4 ). The universal decolonization strategy was estimated to have the lowest mean intervention costs, saving $17 per admission compared with screening and isolation and saving $21 per admission compared with targeted decolonization. By preventing BSis, the universal decolonization strategy was estimated to save $155 per admission in non-intervention, ICU-related costs compared with targeted de-colonization. In total, for every ICU admission, universal decolonization was estimated to save $171 compared with screening and isolation and $100 compared with targeted decolonization.
These results were robust to changes in the parameter estimates that were derived from the REDUCE MRSA trial. 9 Figure lA shows the estimated savings per admission (com-pared with screening and isolation) of universal decolonization, assuming it was less effective at preventing BSis than was reported in the REDUCE MRSA trial. Because the strategy of universal decolonization was estimated to have lower intervention costs than strategies involving screening, we estimated there would be modest cost savings even if it were not more effective in preventing BSis than screening and isolation alone. Results were also robust to varying assumptions regarding the baseline incidence of ICU BSis (Figure lB) and to the incremental cost of a BSI ( Figure IC) . We estimated the differences between the 3 screening strategies under a number of alternative scenarios to the base case (Table 5) . Results were robust to a large number of plausible alterations in the assumptions. For example, if the more costly PCR test is used for MRSA screening, the universal decolonization strategy saves $210 per ICU admission versus $171 if chromogenic agar culture is used (scenario 1). If the more costly trade mupirocin is used for decolonization, the universal decolonization strategy saves $85 per ICU admission versus $171 if generic mupirocin is used (scenario 2). When including only costs estimated to be avoidable in the short-term (ie, when all labor is considered to be a "fixed" cost in the time period under consideration), universal decolonization saves $23 per ICU admission (scenario Ml) compared with screening and isolation. Only under the most pessimistic combination of assumptions did the universal colonization strategy cost more than the other two strategies.
DISCUSSION
Universal decolonization has been shown to be a more effective strategy for reducing BSis due to all pathogens than either MRSA screening and isolation or MRSA screening plus targeted decolonization ! We now show that universal de-colonization is also likely to reduce costs. Because savings come both from reductions in BSis (and associated ICU savings) and from lower intervention costs, the benefits of universal decolonization are robust across a wide range of plausible cost and effectiveness assumptions. Consistent with other studies, 15 we also found that a strategy of screening and targeted decolonization , although not as cost-beneficial as universal decolonization, also resulted in lower costs and fewer BSis than screening and isolation alone. For a hospital with 1,000 ICU admissions per year, we estimate that universal decolonization would prevent 9 BSis and potentially save approximately $171,000 annually com-pared with screening and isolation. The majority of the estimated savings ($155,000) are associated with expected reductions in BSis. Because the combined cost of chlorhex-idine-impregnated cloths and generic mupirocin is similar to the cost of screening cultures, the balance of the savings ($17,000) is primarily related to savings from reducing the number of patients placed on contact precautions. Using our base case cost assumptions, intervention costs will be similar under both strategies only if the percentage of patients placed on contact precautions is similar, which is highly unlikely given the lack of screening testing under universal decolonization, or if we assume no incremental labor costs for donning gloves and gowns.
A strategy of universal decolonization has been shown to reduce BSis by over 40%, 9 and most of the savings from implementing that strategy would come from reducing BSis and the associated ICU-days. The magnitude of the actual savings at any given institution will largely depend on the ability to realize cost reductions from fewer infections. Using estimates from the literature, we assumed that each infection prevented would avert 3.3 ICU-days and potentially save $18,000. The estimated cost per ICU-day that we used was based on hospital charges that were then adjusted downward by costto-charge ratios.1 6 As such, it may be thought of as an estimate of long-run average cost. For any given hospital, the savings from averting infections is likely to be substantially less and will depend, for example, on staffing flexibility and the value of alternative uses for the freed-up bed-days. 1 7 • 1 8 Nevertheless, the cost-savings of the universal decolonization strategy should be realized even by those institutions with excess capacity or staffing that is hard to reduce in the short term. Even when using a very conservative estimate of variable costs (one not including any labor costs), universal decolonization still dominates the other 2 strategies. We note also that our analysis is otherwise conservative in that we have not included any productivity or time costs associated with reduced morbidity.
In addition, because overall intervention costs were similar or lower in our base case estimates, the universal decolonization strategy was the most cost-saving strategy, even under assumptions of minimal effect in reducing BSis compared with screening and isolation alone.
The effectiveness estimates for the prevention strategies were derived from a single trial that included mostly com-munity hospitals, although they were largely representative of US hospitals. 9 Results could vary in hospitals with different patient characteristics, such as proportion of MRSA carriage, or different BSI rates. (The REDUCE MRSA trial focused on community hospital ICUs that may have lower BSI rates than ICUs in academic or specialty cancer care hospitals.) Nevertheless, our sensitivity analyses indicate that the results were robust to changes in those parameters. We did not measure the absolute savings of each strategy compared with no intervention. Among the 
NOTE. Data differ from those given in the text due to rounding; data in parentheses are savings. MRSA, methicillin-resistant Staphylococcus aureu s. ' Scenario 7 was excluded because it was considered implausible for the universal decolonization strategy to have a higher percentage of patients on contact precaution s given that no MRSA testing is performed in this strategy.
hospitals in the REDUCE MRSA trial, screening and isolation was the longstanding gold standard, I 2 and that is the strategy to which the other strategies were compared. Any gains attained by screening and isolation before the baseline period were not quantified. Nevertheless, the cost savings of the universal decolonization arm over screening and isolation alone and targeted decolonization is valid. Because we used a static model, we could not explicitly account for possible changes in resistance or herd effects. However, the results of the trial upon which our base case epidemiological assumptions were based incorporated those effects to the extent that they occurred during the period of the trial. The use of a static model also meant that sensitivity analyses (for example, those in which the incidence of BSis were varied) were not dynamically linked to other parameters, such as MRSA carriage rates, to which they might, in actuality, be related.
Widespread and long-term use of chlorhexidine and mupirocin may engender drug resistance. 1 9 • 2 ° From the perspective of this study, increased resistance would be tantamount to reduced effectiveness of universal decolonization. However, the effect of universal decolonization on reducing BSis does not need to be large for that strategy to be preferred. Finally, our perspective was primarily that of the healthcare system and resource use, and so we did not address issues relating to hospital reimbursement.
A strategy of universal decolonization for patients admitted to the ICU would both reduce BSis and likely reduce health-care costs compared with strategies of MRSA nares screening and isolation or screening and isolation coupled with targeted decolonization. These findings were robust to a wide range of cost and effectiveness assumptions.
